Source MS Trust:
In a clinical trial of anti-LINGO-1, people with optic neuritis who took the new drug had improved nerve signals between the eye and the brain.
A phase II clinical trial called RENEW tested a drug called BIIB033, which is anti-LINGO-1 agent, against placebo in 82 people with acute optic neuritis. Participants received a total of six intravenous infusions of the drug or placebo every four weeks and were followed up for a total of 32 weeks. Although the participants had not been diagnosed with MS, about half of people with optic neuritis go on to develop MS. Read on.